After initially declaring a shortage of Eli Lilly's diabetes and weight loss drugs over, the FDA reversed its opinion, reopening the door for GLP-1 compounders.
Pharmacies in the US that compound drugs can continue to profit from the GLP-1 gold rush – at least for now. But the FDA could pull their products from the market again. It all depends on whether the agency keeps branded GLP-1 drugs on the shortage list or not.
The regulator is currently reviewing a decision it made earlier this month to remove Eli Lilly's diabetes blockbuster Mounjaro and its popular obesity drug Zepbound – both GLP-1 drugs – from the national shortage list. The original decision meant that compounding pharmacies were no longer allowed to make their versions of Lilly's drugs, which use the same active ingredient called tirzepatide and had become extremely popular themselves due to lower prices and availability.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
